The Europe Influenza Market size is expected to reach USD 2.19 billion by 2027 from USD 1.39 billion in 2022, growing at a CAGR of 9.52% during the forecast period.
Key factors attributing to the growth of the European influenza market include the increasing prevalence of influenza, the government's focus on immunization programs, awareness about the disease and its prevention, and advancements in the healthcare sector with improving vaccination rates. The influenza vaccination rate among medical facilities workers in England was recorded to be around 77%. This is the highest success rate for vaccination achieved. Seasonal influenza infects about 10%-30% of the European population each year. In Germany, the incidence of seasonal influenza varies from year to year and is highest is seen in infants and children 2 to 5 years old.
Over the past several years, the complications related to influenza have increased, resulting in a growth death rate. In 2018, the number of deaths from influenza in Spain had recorded over 1,850 deaths. The World Health Organization and the Centers for Disease Control and Prevention recommend annual vaccination for almost everyone over six months, especially those at high risk. The European Center for Disease Prevention and Control also recommends annual vaccination for pregnant women, the elderly, children six months to five years old, and those with certain health problems.
The presence of favorable government policies related to influenza prevention and treatment also supports the market's growth trajectory. Furthermore, in emerging markets, the influenza market is anticipated to benefit from the increasing medical tourism and growth of immigrations during the forecast period.
The European healthcare sector is affected by growing expenses, and this reflects in the studied market. The economic burden per case is more significant in infants with over € 250 and elderly with over € 130. The burden of influenza is most remarkable among infants and young children, overburdening the regional governments. Moreover, research and development of a new vaccine is a considerable process, with limitations of safety and effectiveness. Even the regulatory requirements and regional authorities have a complicated timeline, limiting the growth of the European influenza market.
This research report on the European Influenza Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Disease Indications:
The UK influenza market is geographically the most attractive regional market. It is anticipated to grow at a CAGR of 4.2%, aiming to reach approximately USD 445 million by the end of the forecast period. Factors such as government initiatives, the emergence of new vaccines, disposable income, well-developed infrastructure, and technological advancements for vaccine delivery will drive the market. In the UK, the Universal Childhood Influenza Vaccination Program was launched in 2018 with a live attenuated influenza vaccine. The program has been offered to 2- and 3-year-olds across the UK. Additionally, vaccination has been carried out for children at primary schools in Scotland and some parts of Ireland. These favorable initiatives indicate considerable growth in the UK influenza vaccine market over the forecast period.
Germany was the second-largest influenza market in 2020 and is anticipated to grow at a CAGR of 3.9% by 2027. France is expected to be the third-largest regional market, followed by Italy at the end of the scheduled period. In Italy, people at risk of contracting the virus, such as children, pregnant women, health workers, and the elderly, must be vaccinated. Additional factors such as reimbursement policies and a large population are likely to favor the adoption of the vaccines and medications, thus contributing to the growth of the European influenza market.
KEY MARKET PLAYERS:
Companies playing a pivotal role in the European Influenza Market are Sanofi-Pasteur (U.S.), AstraZeneca (United Kingdom), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), GlaxoSmithKline (U.K.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Abbott Laboratories (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan) and CSL Limited (Australia).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org